PL367414A1 - Kombinacja inhibitora PDE i antagonisty receptoraleukotrienowego - Google Patents
Kombinacja inhibitora PDE i antagonisty receptoraleukotrienowegoInfo
- Publication number
- PL367414A1 PL367414A1 PL02367414A PL36741402A PL367414A1 PL 367414 A1 PL367414 A1 PL 367414A1 PL 02367414 A PL02367414 A PL 02367414A PL 36741402 A PL36741402 A PL 36741402A PL 367414 A1 PL367414 A1 PL 367414A1
- Authority
- PL
- Poland
- Prior art keywords
- combination
- leukotriene receptor
- receptor antagonist
- pde inhibitor
- leukotriene
- Prior art date
Links
- 239000003199 leukotriene receptor blocking agent Substances 0.000 title abstract 2
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 title 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 abstract 1
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 abstract 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 abstract 1
- 208000018569 Respiratory Tract disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01000474 | 2001-09-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL367414A1 true PL367414A1 (pl) | 2005-02-21 |
| PL205927B1 PL205927B1 (pl) | 2010-06-30 |
Family
ID=8176066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL367414A PL205927B1 (pl) | 2001-09-19 | 2002-09-17 | Kompozycja farmaceutyczna zawierająca inhibitor PDE - roflumilast i antagonistę receptora leukotrienowego - montelukast, sposób wytwarzania tej kompozycji, produkt farmaceutyczny i zestaw zawierający te związki oraz zastosowanie kompozycji i produktu farmaceutycznego |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20050014762A1 (pl) |
| EP (1) | EP1429843B1 (pl) |
| JP (1) | JP2005505570A (pl) |
| KR (1) | KR20040044946A (pl) |
| CN (1) | CN100346831C (pl) |
| AT (1) | ATE349243T1 (pl) |
| BR (1) | BR0212582A (pl) |
| CA (1) | CA2460442A1 (pl) |
| CO (1) | CO5560584A2 (pl) |
| CY (1) | CY1106365T1 (pl) |
| DE (1) | DE60217139T2 (pl) |
| DK (1) | DK1429843T3 (pl) |
| EA (1) | EA007736B1 (pl) |
| ES (1) | ES2279004T3 (pl) |
| HU (1) | HUP0500078A3 (pl) |
| IL (2) | IL160272A0 (pl) |
| MA (1) | MA27136A1 (pl) |
| MX (1) | MXPA04002560A (pl) |
| NO (1) | NO331885B1 (pl) |
| NZ (1) | NZ532279A (pl) |
| PL (1) | PL205927B1 (pl) |
| PT (1) | PT1429843E (pl) |
| SI (1) | SI1429843T1 (pl) |
| WO (1) | WO2003024488A2 (pl) |
| ZA (1) | ZA200402653B (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0719518D0 (en) * | 2007-10-05 | 2007-11-14 | Therapeutics Ltd E | Therapy |
| JP2011500731A (ja) * | 2007-10-25 | 2011-01-06 | メルク フロスト カナダ リミテツド | 併用療法 |
| WO2012168907A1 (en) | 2011-06-10 | 2012-12-13 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising revamilast and montelukast or zafirlukast |
| WO2014012954A1 (en) | 2012-07-18 | 2014-01-23 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma |
| AP2015008663A0 (en) | 2013-02-19 | 2015-08-31 | Pfizer | Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of cns and other disorders |
| WO2015063669A1 (en) | 2013-10-30 | 2015-05-07 | Wockhardt Limited | Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof |
| EP3096760A1 (en) | 2014-01-22 | 2016-11-30 | Takeda GmbH | Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier) |
| EP3172210B1 (en) | 2014-07-24 | 2020-01-15 | Pfizer Inc | Pyrazolopyrimidine compounds |
| SG11201700243YA (en) | 2014-08-06 | 2017-02-27 | Pfizer | Imidazopyridazine compounds |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY121142A (en) * | 1999-02-23 | 2005-12-30 | Smithkline Beecham Corp | Controlled release formulation for treating copd |
| CA2715683A1 (en) * | 1999-08-21 | 2001-03-01 | Nycomed Gmbh | Synergistic combination |
| MY134008A (en) * | 1999-12-22 | 2007-11-30 | Merck Frosst Canada Inc | Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors |
| CZ20022410A3 (cs) * | 2000-01-31 | 2003-08-13 | Pfizer Products Inc. | Benzoanelované heterocyklylové deriváty nikotinamidu užitečné jako selektivní inhibitory isozymů PDE4 |
| MY123585A (en) * | 2000-03-23 | 2006-05-31 | Merck Canada Inc | Tri-aryl-substituted-ethane pde4 inhibitors. |
| AU2001261962B2 (en) * | 2000-05-25 | 2005-04-21 | Merck Frosst Canada Ltd | Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor |
-
2002
- 2002-09-17 US US10/489,903 patent/US20050014762A1/en not_active Abandoned
- 2002-09-17 WO PCT/EP2002/010423 patent/WO2003024488A2/en not_active Ceased
- 2002-09-17 PT PT02798730T patent/PT1429843E/pt unknown
- 2002-09-17 SI SI200230500T patent/SI1429843T1/sl unknown
- 2002-09-17 PL PL367414A patent/PL205927B1/pl unknown
- 2002-09-17 MX MXPA04002560A patent/MXPA04002560A/es active IP Right Grant
- 2002-09-17 KR KR10-2004-7003963A patent/KR20040044946A/ko not_active Ceased
- 2002-09-17 BR BR0212582-0A patent/BR0212582A/pt not_active Application Discontinuation
- 2002-09-17 IL IL16027202A patent/IL160272A0/xx active IP Right Grant
- 2002-09-17 CA CA002460442A patent/CA2460442A1/en not_active Abandoned
- 2002-09-17 AT AT02798730T patent/ATE349243T1/de active
- 2002-09-17 DE DE60217139T patent/DE60217139T2/de not_active Expired - Lifetime
- 2002-09-17 CN CNB02818260XA patent/CN100346831C/zh not_active Expired - Fee Related
- 2002-09-17 HU HU0500078A patent/HUP0500078A3/hu unknown
- 2002-09-17 NZ NZ532279A patent/NZ532279A/en not_active IP Right Cessation
- 2002-09-17 DK DK02798730T patent/DK1429843T3/da active
- 2002-09-17 EA EA200400416A patent/EA007736B1/ru not_active IP Right Cessation
- 2002-09-17 JP JP2003528582A patent/JP2005505570A/ja active Pending
- 2002-09-17 ES ES02798730T patent/ES2279004T3/es not_active Expired - Lifetime
- 2002-09-17 EP EP02798730A patent/EP1429843B1/en not_active Expired - Lifetime
-
2004
- 2004-02-08 IL IL160272A patent/IL160272A/en not_active IP Right Cessation
- 2004-03-18 MA MA27581A patent/MA27136A1/fr unknown
- 2004-03-24 CO CO04027775A patent/CO5560584A2/es not_active Application Discontinuation
- 2004-04-05 ZA ZA200402653A patent/ZA200402653B/en unknown
- 2004-04-19 NO NO20041595A patent/NO331885B1/no not_active IP Right Cessation
-
2007
- 2007-03-09 CY CY20071100329T patent/CY1106365T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60217139T2 (de) | 2007-10-04 |
| IL160272A (en) | 2008-03-20 |
| EA007736B1 (ru) | 2006-12-29 |
| HK1066752A1 (en) | 2005-04-01 |
| NO331885B1 (no) | 2012-04-30 |
| NO20041595L (no) | 2004-06-16 |
| CN1655846A (zh) | 2005-08-17 |
| ZA200402653B (en) | 2005-02-14 |
| PT1429843E (pt) | 2007-03-30 |
| CO5560584A2 (es) | 2005-09-30 |
| PL205927B1 (pl) | 2010-06-30 |
| DK1429843T3 (da) | 2007-04-30 |
| HUP0500078A3 (en) | 2010-07-28 |
| IL160272A0 (en) | 2004-07-25 |
| DE60217139D1 (de) | 2007-02-08 |
| ATE349243T1 (de) | 2007-01-15 |
| SI1429843T1 (sl) | 2007-06-30 |
| US20050014762A1 (en) | 2005-01-20 |
| BR0212582A (pt) | 2004-10-13 |
| CN100346831C (zh) | 2007-11-07 |
| WO2003024488A3 (en) | 2003-09-04 |
| EP1429843A2 (en) | 2004-06-23 |
| CY1106365T1 (el) | 2011-10-12 |
| MA27136A1 (fr) | 2005-01-03 |
| HUP0500078A2 (hu) | 2005-04-28 |
| JP2005505570A (ja) | 2005-02-24 |
| MXPA04002560A (es) | 2004-05-31 |
| NZ532279A (en) | 2006-02-24 |
| WO2003024488A2 (en) | 2003-03-27 |
| KR20040044946A (ko) | 2004-05-31 |
| CA2460442A1 (en) | 2003-03-27 |
| ES2279004T3 (es) | 2007-08-16 |
| EA200400416A1 (ru) | 2004-12-30 |
| EP1429843B1 (en) | 2006-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0302476A3 (en) | Use of acetylcholinesterase inhibitors and gabaainverse agonists for the treatment of cognitive disorders and for preparation of pharmaceutical compositins | |
| HUP0600103A2 (en) | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders | |
| MXPA04003668A (es) | Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos. | |
| EP1827468A4 (en) | LEUPROLID ACETATE AND ACETYLCHOLINESTERASE INHIBITORS OR NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ALZHEIMER DISEASE | |
| CY1106365T1 (el) | Συνδυασμος ενος αναστολεα pde και ενος ανταγωνιστη υποδοχεων λευκοτριενιου | |
| CY1106927T1 (el) | Φαρμακευτικη συνθεση ενος pde4 ή pde3/4 αναστολεα και ανταγωνιστη υποδοχεα ισταμινης | |
| HUP0303363A2 (hu) | Kináz-inhibitor hatású heterociklusos vegyületek alkalmazása gyógyszerkészítmények előállítására | |
| WO2002081728A3 (en) | Quinoline inhibitors of hyak1 and hyak3 kinases | |
| IL198759A (en) | Use of 3gal receptor antagonists to prepare medications to treat depression and / or anxiety | |
| WO2002072093A3 (en) | Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders | |
| ID29818A (id) | Penggunaan antagonis reseptor angiotensin ii untuk mengobati infarksi miokardial | |
| BR0000486A (pt) | Antagonistas do neuropeptìdeo y | |
| PL369736A1 (pl) | Nowe kompozycje leków na bazie antycholinergików oraz inhibitorów kinazy EGFR | |
| NO20033634L (no) | GLyT-1-inhibitorer | |
| MXPA03009506A (es) | USO DE COMPUESTOS ELIMINADORES DE RADICALES PARA EL TRATAMIENTO Y PREVENCIoN DE TRASTORNOS DE LA MICRO-CIRCULACION DEPENDIENTES DE NO. | |
| HK1057488A (en) | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders | |
| MY139844A (en) | 1,2,4-triaminobenzene derivatives and their uses thereof for the prevention, treatment and/or inhibition of disorders of the central nervous system |